Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy

Biomaterials

Volumn 98, Issue , 2016, Pages 171-183

  Qian, Yuan ^a,b   Jin, Honglin ^a,b,c   Qiao, Sha ^a,b   Dai, Yanfeng ^a,b   Huang, Chuan ^a,b   Lu, Lisen ^a,b   Luo, Qingming ^a,b   Zhang, Zhihong ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antigen delivery; Cancer immunotherapy; Dendritic cell targeting; Lymph node; Nanovaccine

Indexed keywords

BIOCOMPATIBILITY; BODY FLUIDS; CELLS; DISEASES; OLIGONUCLEOTIDES; OPTICAL PROPERTIES; PEPTIDES; SELF ASSEMBLY; VACCINES;

ANTIGEN DELIVERY; CANCER IMMUNOTHERAPY; DENDRITIC CELLS; LYMPH NODE; NANOVACCINE;

ANTIGENS;

ALPHA ANTIGEN PEPTIDE NANOVACCINE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; NANOCARRIER; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TARGET CELL; THERAPY EFFECT; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CHEMISTRY; DRUG EFFECTS; FLUORESCENCE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; FLUORESCENCE; IMMUNOTHERAPY; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES; SCAVENGER RECEPTORS, CLASS B; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84966711371     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.05.008     Document Type: Article

References (58)

1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
2. Melero I., Gaudernack G., Gerritsen W., Huber C., Parmiani G., Scholl S., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11:509-524.
3. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
4. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39:38-48.
5. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
6. Johansen P., Mohanan D., Martínez-Gómez J.M., Kündig T.M., Gander B. Lympho-geographical concepts in vaccine delivery. J. Con. Rel. 2010, 148:56-62.
7. Lee I.-H., Kwon H.-K., An S., Kim D., Kim S., Yu M.K., et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew. Chem. Int. Ed. Engl. 2012, 51:8800-8805.
8. Jeanbart L., Ballester M., de Titta A., Corthesy P., Romero P., Hubbell J.A., et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Can. Immunol. Res. 2014, 2:436-447.
9. van der Vlies A.J., O'Neil C.P., Hasegawa U., Hammond N., Hubbell J.A. Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug. Chem. 2010, 21:653-662.
10. Noh Y.-W., Kong S.-H., Choi D.-Y., Park H.S., Yang H.-K., Lee H.-J., et al. Near-infrared emitting polymer nanogels for efficient sentinel lymph node mapping. ACS Nano 2012, 6:7820-7831.
11. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotech. 2007, 25:1159-1164.
12. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug. Disc. 2007, 6:404-414.
13. Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr. Drug Deliv. 2011, 8:282-289.
14. De Temmerman M.-L., Rejman J., Demeester J., Irvine D.J., Gander B., De Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug. Disc. Today 2011, 16:569-582.
15. Shao K., Singha S., Clemente-Casares X., Tsai S., Yang Y., Santamaria P. Nanoparticle-based immunotherapy for Cancer. ACS Nano 2015, 9:16-30.
16. Goldberg M.S. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 2015, 161:201-204.
17. Zhang P., Chen Y., Zeng Y., Shen C., Li R., Guo Z., et al. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E6129-E6138.
18. Liu H., Moynihan K.D., Zheng Y., Szeto G.L., Li A.V., Huang B., et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519-522.
19. Sousa C.E. Dendritic cells in a mature age. Nat. Rev. Immunol. 2006, 6:476-483.
20. Henri S., Vremec D., Kamath A., Waithman J., Williams S., Benoist C., et al. The dendritic cell populations of mouse lymph nodes. J. Immunol. 2001, 167:741-748.
21. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002, 23:445-449.
22. Platt C.D., Ma J.K., Chalouni C., Ebersold M., Bou-Reslan H., Carano R.A.D., et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4287-4292.
23. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S.-I., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004, 199:815-824.
24. Comp L., Bonifaz D., Bonnyay K., Mahnke M., Rivera M.C., Nussenzweig, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
25. Zhang Z., Chen J., Ding L., Jin H., Lovell J.F., Corbin I.R., et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 2010, 6:430-437.
26. Zhang Z., Cao W., Jin H., Lovell J.F., Yang M., Ding L., et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Inter. Ed. 2009, 48:9171-9175.
27. Zheng Y., Liu Y., Jin H., Pan S., Qian Y., Huang C., et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013, 3:477-486.
28. Zhou F., Rouse B.T., Huang L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. 1992, 52:6287-6291.
29. Susaki E.A., Tainaka K., Perrin D., Kishino F., Tawara T., Watanabe T.M., et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell 2014, 157:726-739.
30. Zheng Y., Lin Q., Jin H., Chen J. Visualization of head and neck cancer models with a triple fusion reporter gene. J. Inno. Opt. Health Sci. 2012, 5:1250028-1250036.
31. Zheng Y., Huang C., Cheng Z., Chen M. Establishment of visible animal metastasis models for human nasopharyngeal carcinoma based on a far-red fluorescent protein. J. Inno. Opt. Health Sci. 2012, 5:1250019-1250028.
32. Yang X., Gong H., Fu J., Quan G., Huang C., Luo Q. Molecular imaging of small animals with fluorescent proteins: from projection to multimodality. Comput. Med. Imaging Graph. 2012, 36:259-263.
33. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
34. Förster R., Braun A., Worbs T. Lymph node homing of T cells and dendritic cells via afferent lymphatics. Trends. Immunol. 2012, 33:271-280.
35. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995, 182:389-400.
36. Iyoda T., Shimoyama S., Liu K., Omatsu Y., Akiyama Y., Maeda Y., et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002, 195:1289-1302.
37. Lin Q., Chen J., Ng K.K., Cao W., Zhang Z., Zheng G. Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm. Res. 2013, 31:1438-1449.
38. Neefjes J., Jongsma M.L.M., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 2011, 11:823-836.
39. Lin Q., Chen J., Jin H., Ng K.K., Yang M., Cao W., et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 2012, 7:1813-1825.
40. Lin Q., Jin C.S., Huang H., Ding L., Zhang Z., Chen J., et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small 2014, 10:3072-3082.
41. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 2011, 11:865-872.
42. Schreiber T.H., Raez L., Rosenblatt J.D., Podack E.R. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 2010, 22:105-112.
43. Moon J.J. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 2011, 10:243-251.
44. Mamo T., Moseman E.A., Kolishetti N., Salvador-Morales C., Shi J., Kuritzkes D.R., et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010, 5:269-285.
45. Zhou F., Nordquist R.E., Chen W.R. Photonics immunotherapy-a novel strategy for cancer treatment. J. Inno. Opt. Health Sci. 2016, 9:1630001-1630011.
46. Shao S., Geng J., Ah Yi H., Gogia S., Neelamegham S., Jacobs A., et al. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat. Chem. 2015, 7:438-446.
47. Cho N.-H., Cheong T.-C., Min J.H., Wu J.H., Lee S.J., Kim D., et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nano 2011, 6:675-682.
48. Noh Y.-W., Jang Y.-S., Ahn K.-J., Lim Y.T., Chung B.H. Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials 2011, 32:6254-6263.
49. Guo Y., Wang D., Song Q., Wu T., Zhuang X., Bao Y., et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 2015, 9:6918-6933.
50. Allan R.S., Waithman J., Bedoui S., Jones C.M., Villadangos J.A., Zhan Y., et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006, 25:153-162.
51. Gray E.E., Cyster J.G. Lymph node macrophages. J. Innate. Immun. 2012, 4:424-436.
52. Miller M.J., Wei S.H., Parker I., Cahalan M.D. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002, 296:1869-1873.
53. Asano K., Nabeyama A., Miyake Y., Qiu C.-H., Kurita A., Tomura M., et al. CD169-Positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011, 34:85-95.
54. Proudfoot O., Apostolopoulos V., Pietersz G.A. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol. Pharm. 2007, 4:58-72.
55. Apostolopoulos V., Thalhammer T., Tzakos A.G., Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J. Drug. Deliv. 2013, 2013:1-22.
56. Kreutz M., Tacken P.J., Figdor C.G. Targeting dendritic cells-why bother?. Blood 2013, 121:2836-2844.
57. Bonifaz L.C. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004, 199:815-824.
58. Drutman S.B., Trombetta E.S. Dendritic cells continue to capture and present antigens after maturation in vivo. J. Immunol. 2010, 185:2140-2146.